Cargando…

Targeting HMGB1: A Potential Therapeutic Strategy for Chronic Kidney Disease

High-mobility group protein box 1 (HMGB1) is a member of a highly conserved high-mobility group protein present in all cell types. HMGB1 plays multiple roles both inside and outside the cell, depending on its subcellular localization, context, and post-translational modifications. HMGB1 is also asso...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Tongtong, Li, Qian, Jin, Qi, Yang, Liping, Mao, Huimin, Qu, Peng, Guo, Jing, Zhang, Bo, Ma, Fang, Wang, Yuyang, Peng, Liang, Li, Ping, Zhan, Yongli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539693/ https://www.ncbi.nlm.nih.gov/pubmed/37781525 http://dx.doi.org/10.7150/ijbs.87964

Ejemplares similares

Regulation of autophagy by natural polyphenols in the treatment of diabetic kidney disease: therapeutic potential and mechanism
por: Liu, Tongtong, et al.
Publicado: (2023)

Therapeutic potential of artemisinin and its derivatives in managing kidney diseases
por: Jin, Qi, et al.
Publicado: (2023)

A Network Pharmacology-Based Strategy for Unveiling the Mechanisms of Tripterygium Wilfordii Hook F against Diabetic Kidney Disease
por: Wang, Yuyang, et al.
Publicado: (2020)

Comprehensive bibliometric analysis of sirtuins: Focus on sirt1 and kidney disease
por: Liu, Tongtong, et al.
Publicado: (2022)

Efficacy and safety of immunosuppressive therapies in the treatment of high-risk IgA nephropathy: A network meta-analysis
por: Liu, Tongtong, et al.
Publicado: (2021)

Knowledge Domain and Emerging Trends in Podocyte Injury Research From 1994 to 2021: A Bibliometric and Visualized Analysis
por: Liu, Tongtong, et al.
Publicado: (2021)

Obstructive sleep apnea syndrome and risk of renal impairment: a systematic review and meta-analysis with trial sequential analysis
por: Liu, Tongtong, et al.
Publicado: (2020)

Thyroid dysfunction and cardiovascular events in patients with chronic kidney disease: A protocol of systematic review and meta-analysis
por: Liu, Tongtong, et al.
Publicado: (2020)

Oxidative stress and inflammation in diabetic nephropathy: role of polyphenols
por: Jin, Qi, et al.
Publicado: (2023)

Chinese Herbal Medicine in Ameliorating Diabetic Kidney Disease via Activating Autophagy
por: Wang, Yuyang, et al.
Publicado: (2019)

Genetic evidence supporting the causal role of gut microbiota in chronic kidney disease and chronic systemic inflammation in CKD: a bilateral two-sample Mendelian randomization study
por: Ren, Feihong, et al.
Publicado: (2023)

Editorial: Novel therapeutic strategies for chronic kidney disease: from bench to bedside
por: Huang, Chunling, et al.
Publicado: (2023)

Targeting HMGB1: An available Therapeutic Strategy for Breast Cancer Therapy
por: Dong, Haonan, et al.
Publicado: (2022)

Proteome-wide mendelian randomization study implicates therapeutic targets in common cancers
por: Ren, Feihong, et al.
Publicado: (2023)

The Therapeutic Strategies for Uremic Toxins Control in Chronic Kidney Disease
por: Lu, Ping-Hsun, et al.
Publicado: (2021)

Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases
por: Huang, Wei, et al.
Publicado: (2022)

Pharmacological targeting of HMGB-1 translocation: A potential therapeutic strategy for COVID-19
por: Bagheri, Vahid
Publicado: (2022)

Therapeutic potential of HMGB1-targeting agents in sepsis
por: Wang, Haichao, et al.
Publicado: (2008)

The Potential Role of HMGB1 Release in Peritoneal Dialysis-Related Peritonitis
por: Cao, Shirong, et al.
Publicado: (2013)

Disease-syndrome combination modeling: metabolomic strategy for the pathogenesis of chronic kidney disease
por: Li, Shasha, et al.
Publicado: (2017)

Therapeutic strategies to slow chronic kidney disease progression
por: Wühl, Elke, et al.
Publicado: (2008)

The performance of the alarmin HMGB1 in pediatric diseases: From lab to clinic
por: Li, Bo, et al.
Publicado: (2020)

Determination of HMGB1 in hepatitis B virus-related acute-on-chronic liver failure patients with acute kidney injury: Early prediction and prognostic implications
por: Liu, Yu, et al.
Publicado: (2023)

Therapeutic strategies for chronic wound infection
por: Liu, Yi-Fan, et al.
Publicado: (2022)

HMGB1, anti-HMGB1 antibodies, and ratio of HMGB1/anti-HMGB1 antibodies as diagnosis indicator in fever of unknown origin
por: Chen, Mingkun, et al.
Publicado: (2021)

Effects of Circulating HMGB-1 and Histones on Cardiomyocytes–Hemadsorption of These DAMPs as Therapeutic Strategy after Multiple Trauma
por: Weber, Birte, et al.
Publicado: (2020)

HMGB1 in nervous system diseases: A common biomarker and potential therapeutic target
por: Mao, Di, et al.
Publicado: (2022)

HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer
por: Ma, Hanlin, et al.
Publicado: (2022)

Release of HMGB1 in Podocytes Exacerbates Lipopolysaccharide-Induced Acute Kidney Injury
por: Gao, Zhao, et al.
Publicado: (2021)

Overexpression of HMGB3 and its prognostic value in breast cancer
por: Zhou, Xiaomei, et al.
Publicado: (2022)

HMGB1-Induced Hepatocyte Pyroptosis Expanding Inflammatory Responses Contributes to the Pathogenesis of Acute-on-Chronic Liver Failure (ACLF)
por: Hou, Weixin, et al.
Publicado: (2021)

Neat1 promotes acute kidney injury to chronic kidney disease by facilitating tubular epithelial cells apoptosis via sequestering miR-129-5p
por: Ma, Tongtong, et al.
Publicado: (2022)

HMGB1: an important regulator of myeloid differentiation and acute myeloid leukemia as well as a promising therapeutic target
por: Liu, Lulu, et al.
Publicado: (2020)

Paeonol attenuates inflammation by confining HMGB1 to the nucleus
por: Miao, Jifei, et al.
Publicado: (2021)

HMGB1: A Promising Therapeutic Target for Prostate Cancer
por: Gnanasekar, Munirathinam, et al.
Publicado: (2013)

Downregulation of HMGB1 in thymoma cells affects T cell differentiation
por: Li, Jian, et al.
Publicado: (2023)

Johnny on the Spot-Chronic Inflammation Is Driven by HMGB1
por: Gorgulho, Carolina M., et al.
Publicado: (2019)

Recent Progresses in Non-Dialysis Chronic Kidney Disease Patients with Hyperkalemia: Outcomes and Therapeutic Strategies
por: Tian, Ruixue, et al.
Publicado: (2023)

HMGB3 promotes the malignant phenotypes and stemness of epithelial ovarian cancer through the MAPK/ERK signaling pathway
por: Ma, Hanlin, et al.
Publicado: (2023)

HMGB1: a double-edged sword and therapeutic target in the female reproductive system
por: Ren, Yu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ughhai5gghv7d1nkkrpivf4qdn